NEUMORA THERAPEUTICS, INC. Capital Expenditures
NEUMORA THERAPEUTICS, INC. (NMRA) reported Capital Expenditures of $16.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2025-11-06
- NEUMORA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-12-31 was $44.00K, a 91.30% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-09-30 was $37.00K.
- NEUMORA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-06-30 was $0.00.
- NEUMORA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-03-31 was $36.00K.
- NEUMORA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $117.00K, a 77.10% decline from fiscal 2022.
- NEUMORA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $511.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2025-09-30 | $16.00K 10-Q · filed 2025-11-06 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $81.00K derived: sum of 2 quarters · filed 2025-03-03 | $81.00K derived: sum of 3 quarters · filed 2025-03-03 | $117.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $37.00K derived: sum of 2 quarters · filed 2024-11-12 | $73.00K 10-Q · filed 2024-11-12 | $96.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $36.00K 10-Q · filed 2024-08-06 | $59.00K derived: sum of 3 quarters · filed 2025-03-03 | |
| 2023-03-31 | $36.00K 10-Q · filed 2024-05-07 | $59.00K derived: sum of 2 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $511.00K 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $488.00K 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |